Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.
Press releases published on June 26, 2025
Cancer treatments and Panama Canal efficiency: Purdue Innovates Incubator funds projects to advance university innovations
GlobeNewswire
·
June 26, 2025
WEST LAFAYETTE, Ind., June 26, 2025 (GLOBE NEWSWIRE) -- Purdue University researchers in the colleges of Agriculture, Engineering and Science have received $100,000 from the Trask Innovation Fund to develop Purdue-owned intellectual property for commercial …
Annovis to Attend the AAIC 2025 with Four Poster Presentations
GlobeNewswire
·
June 26, 2025
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and …
Labviva Automates Chemical Supply Chain for the Life Sciences Industry
GlobeNewswire
·
June 26, 2025
BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- The life sciences chemical supply chain has traditionally been a bottleneck to R…
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
GlobeNewswire
·
June 26, 2025
ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group …
Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards
GlobeNewswire
·
June 26, 2025
Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” …
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
GlobeNewswire
·
June 26, 2025
CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
GlobeNewswire
·
June 26, 2025
SOLANA BEACH, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, …
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
GlobeNewswire
·
June 26, 2025
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire
·
June 26, 2025
The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 …
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
GlobeNewswire
·
June 26, 2025
JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was …
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
GlobeNewswire
·
June 26, 2025
KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt …
Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
GlobeNewswire
·
June 26, 2025
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation reflects ZORYVE’s proven efficacy, safety, and …
Confluent Health Launches Groundbreaking Scholars Program Designed to Eliminate Student Debt for Future Physical Therapists
GlobeNewswire
·
June 26, 2025
LOUISVILLE, Ky., June 26, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a leading innovator in musculoskeletal (MSK) care, has launched the Confluent Health Scholars Program, an industry-leading initiative designed to eliminate the biggest barrier to entry …
Montauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider Foundation
GlobeNewswire
·
June 26, 2025
MONTAUK, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Montauk Brewing Co., the brewery known for capturing the essence of coastal living and a craft beer brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), is partnering with premium lifestyle …
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
GlobeNewswire
·
June 26, 2025
MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by …
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
GlobeNewswire
·
June 26, 2025
Initiation of patient recruitment marks a key milestone in the development of VAR 200, a potential first-in-class treatment for kidney disease addressing renal lipotoxicity. There are no available drugs targeting renal lipotoxicity that damages the kidneys …
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
GlobeNewswire
·
June 26, 2025
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on …
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
GlobeNewswire
·
June 26, 2025
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 ( …
ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
GlobeNewswire
·
June 26, 2025
UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the …
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
GlobeNewswire
·
June 26, 2025
Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate and largely related to injection site and infusion …